Novo Nordisk has scored a legal win in its fight against unauthorized copies of its weight-loss and diabetes medications, Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) has removed the shortage status for these drugs, signaling that supply levels are now stable, according to Axios.

The pharmaceutical company has intensified its legal efforts, targeting entities that produce compounded versions of these medications without authorization. Reuters reports that Novo Nordisk has filed multiple lawsuits to protect its FDA-approved supply chain. Supporting this action, a U.S. District Judge recently turned down a bid by compounding pharmacies, enabling the FDA's directive for large compounders to halt production to stand firm.

Affected compounding pharmacies must cease producing these copies by specified deadlines, with smaller operations required to stop immediately and larger ones by May 22. Novo Nordisk's stance has been legally upheld, strengthening its market position. The company is projecting substantial revenue for Ozempic and Wegovy this year, with expectations of $20.1 billion and $14.79 billion, respectively, as reported by Reuters.